Randomised Controlled TrialtcVNSn = 336

Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial

Najib U, Smith T, Hindiyeh N, Saper J, Nye B, Ashina S, McClure CK, Marmura MJ, Chase S, Liebler E, et al.

Cephalalgia · 2022

Key finding

Active nVNS achieved a 44.87% responder rate versus 26.81% for sham (P=0.048), with migraine with aura patients showing a therapeutic gain exceeding 100% over sham.

Condition
Migraine
Stimulation
tcVNS
Evidence tier
Randomised Controlled Trial
Participants
336
View on DOI

Cite this study

Najib, U., Smith, T., Hindiyeh, N., Saper, J., Nye, B., Ashina, S., McClure, C. K., Marmura, M. J., Chase, S., Liebler, E., & Lipton, R. B. (2022). Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. Cephalalgia, 42(7), 560-569. https://doi.org/10.1177/03331024211068813

Related studies in Migraine

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.